Control group 2

DRUG3 trials

Sponsors

Hanlim Pharm. Co., Ltd., Nestle Foundation, Self

Conditions

Diabete Type 2HypertensionMental and Behavioural DisordersNutritional, Metabolic, Endocrine

Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

RecruitingNCT07552389

Hanlim Pharm. Co., Ltd.Diabete Type 2, Hypertension

Start: 2025-12-18End: 2028-12-01Target: 228Updated: 2026-04-27

Unknown Phase

Pearl millet instant beverage powder enriched with baobab pulp to improve iron and anaemia status of adolescent girls in rural Ghana

Active, not recruitingPACTR202306743290094

Nestle FoundationNutritional, Metabolic, Endocrine

Start: 2024-02-22Target: 258Updated: 2026-01-27

Effects of self-administered acupressure for substance use disorders: A randomised clinical trial

Active, not recruitingPACTR202407473530071

SelfMental and Behavioural Disorders

Start: 2024-10-01Target: 100Updated: 2026-01-27